Back to blog

Education - Primary Ovarian Insufficiency

Why Primary Ovarian Insufficiency (POI) Should Be Recognized as a Multi-System Condition Similar to PMOS/PCOS

Why Primary Ovarian Insufficiency deserves the same attention we now give PCOS - and why every woman, every clinician, and every health system needs to take it seriously.

By Dr. Vaishali Popat, MD, MPH - Vital Endocrinology

The multi-system impact of Primary Ovarian Insufficiency infographic

A whole-body condition: what POI actually touches

If you only remember one thing about POI, remember this: it is the whole body, not just the ovaries.

Reproductive system

Irregular or absent periods are often the first sign - easily dismissed in young women as "stress" or "pill side effects."

Infertility is the headline diagnosis for many women, but spontaneous pregnancy is still possible in 5-10% of cases.2

Vaginal and vulvar tissues become dry, thin, and fragile, leading to discomfort, recurrent irritation, and painful sex (dyspareunia).

Bone health

Women with POI have a 1.5-fold higher risk of fracture compared with women experiencing menopause at the typical age, and an osteoporosis prevalence between 8% and 27%.7,8

A diagnostic delay of one year or more is independently associated with lower bone mass.7 Time is bone.

Cardiovascular health

POI raises the risk of premature cardiovascular disease, stroke, and earlier mortality if adequate treatment is not provided.7,9

The data shows that cardiovascular protection is greatest when hormone therapy is started within one year of diagnosis and continued for at least a decade.7

Thyroid and adrenal glands

Thyroid autoimmunity is the most common autoimmune association in POI. Published reviews report thyroid autoimmune disease or thyroid antibody positivity in approximately 14-32.7% of women with POI, while overt or subclinical thyroid dysfunction is reported in roughly 8-20%, depending on the cohort and definitions used.10

A much smaller but important subset develops autoimmune adrenal insufficiency (positive 21-hydroxylase antibodies) - a condition that can be life-threatening if missed, which is why we screen for it.1,10

Brain, mood, and cognition

Anxiety, depression, brain fog, and disrupted sleep are common - and not "just stress." Estrogen has direct effects on serotonin, dopamine, and cognitive processing.7

Long-term untreated POI is associated with measurable decreases in global cognitive function.7,9

Skin, hair, and connective tissue

Estrogen has a major supportive effect on collagen. In simple terms, it helps the body make, maintain, and protect collagen-rich tissues, especially in the skin, connective tissue, bone, blood vessels, and urogenital tissues. When estrogen levels fall, collagen production tends to decline and collagen breakdown tends to increase. Without it, skin becomes dry, hair thins, wound healing slows, and joints can ache.

Sexual function and quality of life

Low libido, painful intercourse, and the emotional weight of an infertility diagnosis in a young woman compound into a quality-of-life impact that is too often left unaddressed.9

The cost of delay is real. Every year without treatment is bone loss, vascular stiffening, and cognitive change that does not fully reverse later.

What needs to change

If PCOS is finally getting the recognition it deserves as a whole-body metabolic-endocrine syndrome, POI deserves the same. A few things would help:

  • Train more clinicians - primary care, OB/GYN, endocrinology, and adolescent medicine - to recognize POI early and to manage it across the lifespan.
  • Update guidelines and patient education materials to reflect the new prevalence data: this is not a 1% condition.
  • Fund research into causes, biomarkers, and ovarian regeneration. Stem cell and gene therapy approaches are early but real.
  • Treat POI as the public health issue it is, especially in the context of declining fertility rates and rising maternal age.
  • Listen to patients. Their lived experience is more accurate than the textbook estimate of "rare."

A note to women who suspect they may have POI

If your periods have become irregular or stopped before age 40, if you are experiencing hot flashes or night sweats in your 20s or 30s, if you are struggling to conceive, or if a sister or mother has had early menopause, ask to be evaluated. The workup is straightforward: two FSH levels two weeks apart, estradiol, TSH, AMH, prolactin, karyotype, FMR1 testing, and adrenal antibodies are the foundation. Imaging may be added.1,15

And if you are told nothing can be done - please get a second opinion. There is a great deal that can be done, and you deserve a clinician who knows how to do it.

Different bodies. Different symptoms. Same need for answers.

POI deserves recognition. POI deserves research. POI deserves real care.

Considering a consultation?

Dr. Vaishali Popat sees women with POI virtually across Maryland, Florida, and Virginia.

This article is for educational purposes only and does not constitute medical advice. Please consult a qualified physician for personalized guidance.

References

  1. 1. Franca MM, Mendonca BB. Primary ovarian insufficiency: update on clinical and genetic findings. Frontiers in Endocrinology. 2024;15:1464803. doi:10.3389/fendo.2024.1464803. View source
  2. 2. Nelson LM. Primary ovarian insufficiency. New England Journal of Medicine. 2009;360(6):606-614. doi:10.1056/NEJMcp0808697. View source
  3. 3. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstetrics & Gynecology. 1986;67(4):604-606. Historical 1% estimate. View source
  4. 4. Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22(4):403-411. doi:10.1080/13697137.2019.1574738. View source
  5. 5. Li M, Zhu Y, Wei J, et al. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. Climacteric. 2023;26(2):95-102. doi:10.1080/13697137.2022.2153033. View source
  6. 6. Lass-Hennemann J, et al. Primary ovarian insufficiency: nationwide incidence rate and etiology among Israeli adolescents. Journal of Adolescent Health. 2020;66(5):603-609. View source
  7. 7. Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, Seibel MJ, Eisman JA, Handelsman DJ. The overlooked and undertreated perils of premature ovarian insufficiency. Cleveland Clinic Journal of Medicine. 2025;92(8):475-484. View source
  8. 8. Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. Journal of Clinical Endocrinology & Metabolism. 2009;94(7):2277-2283. doi:10.1210/jc.2008-1878. View source
  9. 9. Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926-937. doi:10.1093/humrep/dew027. View source
  10. 10. Silva CA, Yamakami LYS, Aikawa NE, et al. Autoimmune primary ovarian insufficiency. Autoimmunity Reviews. 2014;13(4-5):427-430. doi:10.1016/j.autrev.2014.01.003.
  11. 11. Sherman SL, Curnow EC, Easley CA, et al. Fragile X-associated primary ovarian insufficiency (FXPOI). National Library of Medicine - MedlinePlus Genetics. Updated 2024. View source
  12. 12. Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. Journal of Molecular Endocrinology. 2010;45(5):257-279. View source
  13. 13. Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertility and Sterility. 2016;106(7):1588-1599. doi:10.1016/j.fertnstert.2016.09.046. View source
  14. 14. Kodaman PH. Hormone replacement therapy for women with premature ovarian insufficiency: a comprehensive review. Human Reproduction Open. 2017;2017(2):hox007. doi:10.1093/hropen/hox007. View source
  15. 15. American College of Obstetricians and Gynecologists. Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstetrics & Gynecology. 2017;129(5):e134-e141. Reaffirmed 2020. View source
  16. 16. ESHRE Guideline Group on POI; Webber L, et al. Evidence-based guideline: premature ovarian insufficiency (2024-2025 update). American Society for Reproductive Medicine / Human Reproduction. 2024. View source